| 发明名称 |
Biomarker SPAG5 |
| 摘要 |
There has been a recent shift in cancer therapy from one size fits all to a personalized and tailored treatment for individual patients to increase efficiency and avoid unnecessary toxicity. This invention relates to a method of determining the prognosis and suitable treatment of cancer in a subject by measuring the level of expression of SPAG5. In particular, it relates to a method where high expression of SPAG5 in tumour cells correlates with aggressive tumours. |
| 申请公布号 |
US2015185219(A1) |
申请公布日期 |
2015.07.02 |
| 申请号 |
US201314404163 |
申请日期 |
2013.05.31 |
| 申请人 |
Nottingham Trent University ;Nottingham University Hospitals NHS Trust |
发明人 |
Ball Graham Roy;Chan Stephan Yan Tat;Abdel-Fatah Tarek Mohamed Ahmed |
| 分类号 |
G01N33/574;C07K16/18;G01N33/577 |
主分类号 |
G01N33/574 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A method for obtaining an indication useful in determining the appropriate treatment for a subject comprising the steps of:
i. determining the expression level of SPAG5 in a tumour tissue sample from said subject; and ii. comparing the expression level of SPAG5 determined in step (i) with one or more reference values. |
| 地址 |
Nottingham GB |
